Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

August 4, 2026 updated by: Menghua Tao, Henry Ford Health System

Impacts of Peanut Intake on Hepatic Markers and Gut Microbiota in Adults With MASLD

The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver.

  • Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm.
  • Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention
  • Daily log to be completed for tracking peanut consumption
  • 2-day Dietary recall at baseline, during Week 6 and Week 12
  • Poat intervention Fibro scans for participants with baseline scans available

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

125

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Menghua Tao, PhD
  • Phone Number: 313-590-9408
  • Email: mtao1@hfhs.org

Study Locations

  • United States
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Recruiting
        • Henry Ford Health System
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 30-70 years
  • do not consume peanut/peanut butter/treenut/seeds > /week
  • at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)
  • Able to understand, speak, and read English
  • Mentally competent to consent

Exclusion Criteria:

  • Food allergy to peanuts or peanut-containing products
  • With alcohol use disorder (AUDIT screening)
  • Leukemia
  • Lymphoma
  • Other types of cancer
  • Heart or cardiovascular diseases (such as heart attack, stroke, heart failure)
  • Kidney diseases (such as chronic kidney disease, kidney transplant, renal insufficiency such as renal failure requiring dialysis)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Peanut
MASLD patients will consume 50 gm of peanut daily for 12 weeks
Other: Peanut consumption
MASLD patients will consume 50 gm of peanut daily for 12 weeks
No Intervention: Control
Regular diet

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hepatic Markers
Time Frame: Baseline to post-intervention (12 weeks)
Changes in hepatic markers such as ALT, ASP, ALP will be evaluated through blood tests at baseline and post-intervention
Baseline to post-intervention (12 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Metabolic Profile
Time Frame: Baseline to post-intervention (12 weeks)
Investigate change in metabolic profiles i.e., total cholesterol, HDL-C, LDL-C, triglycerides, glucose, hemoglobin A1C (HBA1C), and insulin over 12 weeks
Baseline to post-intervention (12 weeks)
Gut microbiota composition
Time Frame: Baseline to post-intervention (12 weeks)
Investigate whether MASLD patients in the Peanut arm will have improved gut microbiota compositions than those in the Control arm
Baseline to post-intervention (12 weeks)
Intrahepatic fat content
Time Frame: Baseline to post-intervention (12 weeks)
Explore whether MASLD patients in the Peanut arm may have lower intrahepatic fat content (IHF) than those in the Control arm over 12 weeks
Baseline to post-intervention (12 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Henry Ford Health System

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 9, 2026

Primary Completion (Estimated)

April 6, 2028

Study Completion (Estimated)

June 9, 2028

Study Registration Dates

First Submitted

June 9, 2026

First Submitted That Met QC Criteria

June 9, 2026

First Posted (Actual)

June 12, 2026

Study Record Updates

Last Update Posted (Actual)

August 6, 2026

Last Update Submitted That Met QC Criteria

August 4, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 19113
  • F20581 (Other Grant/Funding Number: The Peanut Institute Foundation)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe